• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Pharmacyclics Inc. (PCYC)

    -NasdaqGS
    261.25 0.00(0.00%) May 22, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Pharmacyclics Inc.
    999 East Arques Avenue
    Sunnyvale, CA 94085
    United States - Map
    Phone: 408-774-0330
    Fax: 408-774-0340
    Website: http://www.pharmacyclics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:634

    Business Summary 

    Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenström's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company’s product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics, Inc. has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California. As of May 26, 2015, Pharmacyclics Inc. operates as a subsidiary of AbbVie Inc.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pharmacyclics Inc.

    Corporate Governance 
    Pharmacyclics Inc.’s ISS Governance QuickScore as of May 1, 2015 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert W. Duggan , 71
    Chairman and Chief Exec. Officer
    0.000.00
    Mr. Manmeet Singh Soni , 37
    Chief Financial Officer, Principal Accounting Officer and Treasurer
    854.00K79.00K
    Dr. Mahkam Zanganeh D.D.S., MBA, 45
    Chief Operating Officer
    898.00K5.44M
    Mr. Heow Tan , 56
    Chief of Quality & Technical Operations
    607.00K1.17M
    Ms. Shawn Cline Tomasello ,
    Chief Commercial Officer
    424.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders